Ranbaxy net dips by 8% - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Ranbaxy net dips by 8%

Jan 15, 2001

Ranbaxy has reported a net profit of Rs 1,809 m on a turnover of Rs 17,418 m for the full year ended December 2000. While turnover has grown 12% the net profit has actually declined by 8%. However, for the fourth quarter ended 30th December 2000, net profit has gone up by 50% to Rs 483 m. Sales for the fourth quarter has increased from Rs 4,168 m to Rs 4,785 m.

(Rs m) FY00 FY01 Change
Sales 15,598 17,418 11.7%
Other Income 715 471 -34.1%
Profit after Tax/(Loss) 1,969 1,809 -8.1%
Net profit margin (%) 12.6% 10.4%  
No. of Shares (eoy) (m) 115.9 115.9  
Earnings per share 17.0 15.6  
P/E   41.4  

The disappointment for Ranbaxy, however, was the non-receipt of the milestone payment from Bayer, which the company has said will accrue in the first quarter of the current year. Besides, the company’s export of the generic cefuroxime axcetil has also run aground due to the litigation filed by Glaxo in the US courts. The coming year’s performance would be dependent on how soon the company’s US subsidiary breaks even.

The stock quotes at a price of Rs 646 which implies an earnings multiple of 41 times. The year 2000 saw the stock come off almost 50%. Whether 2001 would be any better remains to be seen.

Equitymaster requests your view! Post a comment on "Ranbaxy net dips by 8%". Click here!

  

More Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

RANBAXY LAB SHARE PRICE


Apr 1, 2015 (Close)

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MARKET STATS